A photograph of laboratory glassware including Erlenmeyer flasks and a beaker, some containing clear liquid. A green plant sprout with several leaves is placed in the neck of the central flask. The background is a blurred laboratory setting with blue and white tones.

Zoono Group Limited (ASX:ZNO) Full Year FY21 results

26 August 2021

Full Year FY21 Performance Snapshot

ZOONO®

Revenue

\$27.1M

-29.2%
vs FY20

Gross profit

\$16.1M

-43.2%
vs FY20

Reported NPBT

\$5.9M

-71.1%
vs FY20

Reported NPAT

\$4.6M

-72.2%
vs FY20

Total Assets

\$31.7M

-8.6%
vs FY20

ZOONO®

Highlights

- Revenue performance down in the current year due to high stock over-ordering of NZ\$11M particularly in April 2020
- Solid earnings performance, balance sheet and cash flow - despite margin erosion & investment in new subsidiaries
- Capitalising on direct B2B relationships



Full Year FY21 Financial Review

ZOONO[®]



Full Year FY21 profit and loss summary

Reported revenue down due primarily to over-ordering in April 2020

NZ\$M	30 JUN 2021	30 JUN 2020	Variance \$	%
Total revenue	27.1	38.3	(11.2)	(29.2%)
Gross profit	16.1	28.3	(12.2)	(43.2%)
Operating expenses	(9.8)	(7.6)	(2.2)	(28.9%)
EBITDA	6.3	20.7	(14.4)	(69.6%)
Amortisation ROU assets	(0.26)	(0.15)	(0.11)	(173.3%)
Depreciation & amortisation	(0.10)	(0.05)	(0.05)	(100.0%)
EBIT	5.9	20.5	(14.6)	(71.2%)
NPAT	4.6	16.7	(12.1)	(72.4%)
GM	59.3%	73.9%		(14.6%)
EBIT margin	21.8%	53.8%		(32.0%)

Revenue

- Down 29.2% in face of COVID-19 impacts and reduced trading in some sectors around the globe and lots of customers over-ordering and stock piling especially in April 2020 (NZ\$11M)
- US Revenue growth was NZ\$2.5M in its maiden year as a Group subsidiary

Gross margin

- Reduced revenue and margins from large B2B customers
- Margins impacted by higher freight charges
- Gross Profit decreased 43.2% (vs PCP) on lower revenues and margins

Operating costs

- Higher overheads despite revenue contraction caused by higher regulatory costs and additional staff in the UK and the new US operation
- Doubtful debt provision of NZ\$552k for Clear Facilities – NZ.
- US Regulatory progression costs NZ\$370k
- Increase in marketing costs of NZ\$392k due to:
 - Additional marketing programs for the US and UK

Balance sheet

Stable balance sheet, reflecting reinvestment in growth initiatives

NZ\$M	30 Jun 2021	30 Jun 2020
Cash	4.9	10.3
Trade & other receivables	5.3	9.2
Inventories	12.9	13.2
Property, plant & equipment	0.7	0.2
Lease ROUA	2.0	1.5
Intangibles	5.7	0.03
Other	0.2	0.3
TOTAL ASSETS	31.7	34.7
Trade & other payables	2.2	8.4
Current tax liabilities	0.7	3.8
Lease liability	2.0	1.5
Provisions	5.7	-
TOTAL LIABILITIES	10.6	13.7
NET ASSETS	21.1	21.0

Working capital management

Efficient management of receivables & inventory

Decrease in payables

Payment of Dividend of \$5.1M

Payment of income taxes \$4.3M

No debt

PPE & leases

Growth in-line with business expansion into other locations

Intangibles from acquisitions

US operation acquisition

Provisions

Contingent consideration for the US operation payable over time

Cash flow

Decline in operating cash & cash conversion

Statutory cashflows NZ\$M	30 JUN 2021	30 JUN 2020
Net cash provided by operating activities	1.5	8.1
Acquisition of subsidiary, net of cash	(0.8)	-
Purchases of property, plant and equipment	(0.6)	(0.1)
Net cash used in investing activities	(1.4)	(0.1)
Proceeds from the exercise of options	0.2	-
Dividends paid to shareholders	(5.1)	-
Repayment of borrowings and lease liabilities	(0.3)	(0.2)
Net cash used in financing activities	(5.2)	(0.2)
Net change in cash and cash equivalents	(5.1)	7.8
Effects of foreign exchange on cash balance	(0.3)	(0.6)
Cash and cash equivalents at beginning of year	10.3	3.1
Cash and cash equivalents at end of year	4.9	10.3

- Operating cashflows in FY21 down due to payment of taxes of \$4.3M and higher operating costs with the acquisition of the US operation
- Acquisition investing outflow (\$0.8M), due to:
 - US Stock purchased \$0.6M
 - deferred earn-out consideration payment of (\$0.2M)
- Dividends paid out of \$5.1M

Strategy, Operations & Outlook

ZOONO[®]



Strategic framework for growth

Operations, process & capacity

- *Inventory logistics management systems in place around the globe (the systems talk to each other) to ensure adequate capacity and forecasting*
- *Leveraging cost base to deliver margin expansion on incremental revenue*
- *Large stock holdings to meet demand*

Increase B2B Customers

- *Additional BDMs and Sales reps being secured for expansion and driving growth in FY22*
- *Additional targeted marketing spend to secure large key corporates in key markets*
- *Utilise current reference sites to attract key corporates*

Product and service expansion

- *Private label strategy – commenced with Fine Hygienic and rolling out to 80 countries*
- *New sites opening up and further planned – i.e. Shanghai*
- *Further international testing confirming Zoono's efficacy as required*

Target = earnings growth and shareholder returns

ZOONO[®]



Delivering leading market products to secure large corporates

Driving regional growth in FY22

Capitalising on the COVID pandemic to deliver expansion in key markets

Significant market opportunities

- *COVID rates surging in regional growth corridors*
- *Hand and surface sanitisers becoming increasingly important to fight against current, and future diseases*
- *Large corporates looking to add additional protection to staff in their working environments*
- *Air conditioning systems utilized as a dispenser to protect surfaces and prevent diseases through cleaning the air*
- *Successful trials in spraying on cardboard packaging for fruit and vegetables preventing mould resulting in longer lasting fresh fruit and vegetables*

Potential Air conditioning Opportunity


- *150 buildings utilizing 400 litres per month (speaking to an interested party but contract not finalized yet)*
- *If the contract is secured could result in NZ\$11.5M revenue per annum*
- *Safeguards employees and customers*
- *Interest is already coming in from other building operators*



Zoono Animal Health

ZAH Expects Sales Volumes to increase over the next 6 months

- Foundations around the globe built over the last 24 months
- Strong interest from pig, poultry and veterinary industries
- Zoono products have demonstrated feed efficiency and growth rate production gains in poultry
- Pig productivity trials to establish economic benefit are progressing well in both Australia & the US with excellent results obtained
- Trials commenced with a large UK poultry producer of 300 million birds per annum. To date, results have shown increased bird weights, overall better production performance and improved bird health
- Trials are at a 6 month midpoint with a large poultry producer in Central America. The first trial was successful and the second trial is showing further improvement again
- Many trials take up to a year before a commitment is made from the producer. Overall trials to date have been outstanding, and the expectations are that on completion, sales will increase and continue over time, building momentum throughout the industry.



Innovative proprietary sanitiser and disinfectant

- Provides ongoing mechanical activity (length of time against animal pathogens currently subject of trials)
- Demonstrated effectiveness in global trials against a range of viruses including COVID-19 surrogate, Avian influenza, African Swine Fever, PEDv and PRRSv.
- Range of products including Z-71 Microbe Shield – applied to surfaces via fogging or spraying
- Range of products listed by the various regulatory bodies in Australia, USA, and Canada.

FY22 Outlook

- *Pursue large corporates with large selling teams and presence in many countries to drive B2B sales*
- *Increase mould remediation presentations to large fruit, meat and vegetable producers in target markets*
- *Target large commercial building owners for building sanitization to help protect employees and customers*
- *Increase sales and earnings for FY22 over FY21*

ZOONO[®]

Important Notice & Disclaimer

ZOONO®

Commercial in Confidence

Zoono has not audited or investigated the accuracy or completeness of the information, statements and opinions contained in this presentation. Whilst provided in good faith, to the maximum extent permitted by applicable laws, Zoono makes no representation and can give no assurance, guarantee or warranty, express or implied, as to, and takes no responsibility and assumes no liability for (1) the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission from, any information, statement or opinion contained in this presentation and (2) without prejudice to the generality of the foregoing, the achievement or accuracy of any forecasts, projections or other forward looking information contained or referred to in this presentation.

This overview of the Company does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of Zoono's prospects. You should conduct your own investigation and perform your own analysis in order to satisfy yourself as to the accuracy and completeness of the information, statements and opinions contained in this presentation before making any investment decision.

Future Performance

This presentation contains forecasts, projections and forward looking information. Such forecasts, projections and information are not a guarantee of future performance and involve unknown risks and uncertainties, many of which are out of Zoono's control. Actual results and developments will almost certainly differ materially from those expressed or implied.

Zoono disclaims any intent or obligation to update publicly any forward-looking statements, whether as a result of new information, future events or results or otherwise. The words "believe", "expect", "anticipate", "indicate", "contemplate", "target", "plan", "intends", "continue", "budget", "estimate", "may", "will", "schedule" and other similar expressions identify forward-looking statements. All forward-looking statements made in this presentation are qualified by the foregoing cautionary statements. Investors are cautioned that forward-looking statements are not guarantees of future performance and accordingly investors are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty therein.

ZOONO[®]



NZ +64 9 600 1188

www.zoono.com | Zoono Group Limited (ASX:ZNO)